2020
8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D
HUGHES A, BISPHAM J, FULLER L, WOLF W, FITCH S, WEINZIMER S. 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D. Diabetes 2020, 69 DOI: 10.2337/db20-8-lb.Peer-Reviewed Original ResearchSevere hypoglycemiaPerspectives of peopleUse of glucagonAdministration of glucagonMinimal side effectsMode of administrationHypoglycemic emergenciesGlycemic targetsInsulin therapyDiabetes careSpouse/partnerEmergency treatmentEffective treatmentHypoglycemiaSide effectsT1DGlucagonEmotional impactEmergency useCaregiversT1D.Administration typeFeelings of distressAdministrationParticipantsPrecision Dosing of Rapid-Acting Insulin Matters
Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technology & Therapeutics 2020, 22: 346-351. PMID: 32125891, DOI: 10.1089/dia.2019.0374.Peer-Reviewed Original ResearchConceptsGood glycemic controlGlycemic controlHalf-unit insulin pensInsulin pensDiabetes managementInsulin deliveryStringent glycemic controlInadequate glycemic controlType 2 diabetesType 1 diabetesPrecision of dosingDelivery devicesInsulin delivery devicesInsulin therapyGeriatric patientsHypoglycemic eventsPatient preferencesFlexible dosingPhysical activityDosingLiterature searchPrecision dosingDiabetesInsulinCorrective doses
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdults1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control
2018
Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D
PETTUS J, WEINZIMER S, MCCRIMMON R, AMPUDIA BLASCO F, STEWART J, STRUMPH P, OLIVEIRA J, LAPUERTA P, CASTRO R. Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D. Diabetes 2018, 67 DOI: 10.2337/db18-5-lb.Peer-Reviewed Original ResearchInsulin dose changesDaily insulin doseTotal daily insulin doseOptimized insulin therapyInsulin doseInsulin therapySevere hypoBolus insulinGlycemic controlLexicon PharmaceuticalsMycotic infectionsDose changesTreatment-emergent adverse eventsInsulin reductionLS meanDaily insulin requirementGenital mycotic infectionsSanofi-AventisAdequate glycemic controlGood glycemic controlBody mass indexRisk of hypoglycemiaRenal glucose reabsorptionNumber of patientsType of insulin
2016
Future Drug Treatments for Type 1 Diabetes
Sherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes. 2016, 985-999. DOI: 10.1002/9781118924853.ch66.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInsulin analoguesDiabetes mellitusContinuous subcutaneous insulin infusion pumpType 2 diabetes mellitusType 1 diabetes mellitusInsulin deliveryBasal insulin analoguesNew treatment optionsFuture drug treatmentsAvailable insulin analoguesMore rapid absorptionClosed-loop deliveryDaily diabetes careAvailable insulin preparationsInsulin infusion pumpIntranasal glucagonInsulin therapyGlycemic controlAdjunctive agentsAvailable therapiesInjected medicationsDiabetes careTreatment optionsContinuous glucose monitorDrug treatment
2009
Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes
Tsalikian E, Tamborlane W, Xing D, Becker D, Mauras N, Fiallo-Scharer R, Buckingham B, Weinzimer S, Steffes M, Singh R, Beck R, Ruedy K, Kollman C. Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1954-1959. PMID: 19675205, PMCID: PMC2768200, DOI: 10.2337/dc08-2298.Peer-Reviewed Original ResearchConceptsType 1 diabetesPlasma glucose concentrationEpinephrine responsePlasma glucoseYoung childrenInsulin pump-treated patientsHypoglycemia-associated autonomic failurePump-treated patientsLower plasma glucose concentrationsIntensive insulin therapySymptoms of hypoglycemiaInsulin infusion protocolCounterregulatory hormone concentrationsGlucose concentrationAbsence of signsClosed-loop insulin delivery systemsContinuous glucose monitoringAcute complicationsAutonomic failureCounterregulatory hormonesSympathoadrenal responseInsulin therapyPatient ageNondiabetic adolescentsSymptom scores